Quantbot Technologies LP Has $1.12 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Quantbot Technologies LP increased its stake in Regeneron Pharmaceuticals by 234.1% during the first quarter, bringing its holdings to 1,764 shares valued at approximately $1.12 million.
• Regeneron recently reported a quarterly EPS of $12.89, significantly exceeding the consensus estimate of $8.43, with a year-over-year revenue increase of 3.6%.
• The company declared a quarterly dividend of $0.88, which will be paid out on September 3rd, contributing to an annualized dividend yield of 0.6%.

Quantbot Technologies LP raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 234.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,764 shares of the biopharmaceutical company's stock after buying an additional 1,236 shares during the quarter. Quantbot Technologies LP's holdings in Regeneron Pharmaceuticals were worth $1,119,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Adirondack Trust Co. grew its holdings in Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after buying an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA grew its holdings in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after buying an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after buying an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $589.48 on Friday. The stock's fifty day simple moving average is $550.48 and its 200 day simple moving average is $591.34. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 1.96 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.56 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on REGN. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective on the stock. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Citigroup reissued a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.